ArticleJTO clinical and research reports2024
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06688422 (Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Who cites it
21 citing papers in PubMed, 15 citations in OpenAlex.
- Trial
- PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.Journal of hematology & oncology · 2025Trial
- Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Cancer science · 2025Trial
- Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study.Translational lung cancer research · 2026Article
- Innovative Strategies in the Treatment of Unresectable Locally Advanced NSCLC: A Focus on Radiation Therapy.Cancers · 2026Review
- Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.JTO clinical and research reports · 2026Article
- Article
- Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study.Translational lung cancer research · 2026Article
- Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Drug-Induced Interstitial Lung Disease in Lung Cancer Patients.Respiration; international review of thoracic diseases · 2026Review
- Article
- Radiation-induced lung injury in the era of combination anticancer therapy: a narrative review.Frontiers in immunology · 2026Review
- Immune and inflammatory radiogenomics of radiotherapy-induced normal-tissue toxicity: genetic susceptibility, mechanisms, risk prediction, and clinical translation.Frontiers in immunology · 2026Review
- Article
- Association of pulmonary lymphocytes with radiation-induced lung disease in a mouse model.Radiation oncology (London, England) · 2025Article
- The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.Translational lung cancer research · 2025Article
- A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy.Biomedicines · 2025Review
- Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy.Acta oncologica (Stockholm, Sweden) · 2025Article
- Impact of duration of maintenance immunotherapy on the prognosis of locally advanced non-small cell lung cancer treated with chemoradiotherapy.Frontiers in oncology · 2025Article
- Impact of pneumonitis from radiotherapy combined with immune checkpoint inhibitors therapy on tumor progression and survival in patients with non-small cell lung cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) ( Methods: Patients with WHO performance status of 0 or 1 were randomized (2:1) to 12 months of durvalumab or placebo, 1 to 42 days after cCRT. Associations between baseline factors and on-study G2+PRP in durvalumab-treated patients were investigated using univariate and multivariate logistic regression. PFS and OS were analyzed using Cox proportional hazards models adjusted for time-dependent G2+PRP plus covariates for randomization stratification factors without and with additional baseline factors. Results: On-study G2+PRP occurred in 94 of 475 (19.8%) and 33 of 234 patients (14.1%) on durvalumab and placebo, respectively (median follow-up, 25.2 mo); grade greater than or equal to 3 PRP was uncommon (4.6% and 4.7%, respectively). Time to onset and resolution of G2+PRP was similar with durvalumab and placebo. Univariate and multivariate analyses identified patients treated in Asia, those with stage IIIA disease, those with performance status of 1, and those who had not received induction chemotherapy as having a higher risk of G2+PRP. PFS and OS benefit favoring durvalumab versus placebo was maintained regardless of time-dependent G2+PRP. Conclusions: Factors associated with higher risk of G2+PRP with durvalumab after cCRT were identified. Clinical benefit was maintained regardless of on-study G2+PRP, suggesting the risk of this event should not deter the use of durvalumab in eligible patients with unresectable stage III NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.